Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access

    ARTICLE

    The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory

    MAHER KURDI1,*, ALAA ALKHOTANI2, ABDULRAHMAN SABBAGH3, EYAD FAIZO4, AHMED I. LARY5, AHMED K. BAMAGA6, MAJID ALMANSOURI7, BADR HAFIZ8, THAMER ALSHARIF9, SALEH BAEESA8

    Oncology Research, Vol.32, No.6, pp. 1037-1045, 2024, DOI:10.32604/or.2024.051112 - 23 May 2024

    Abstract Background: The dysregulation of Isocitrate dehydrogenase (IDH) and the subsequent production of 2-Hydroxyglutrate (2HG) may alter the expression of epigenetic proteins in Grade 4 astrocytoma. The interplay mechanism between IDH, O-6-methylguanine-DNA methyltransferase (MGMT)-promoter methylation, and protein methyltransferase proteins-5 (PRMT5) activity, with tumor progression has never been described. Methods: A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors. Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis. Inter-cohort statistical significance was evaluated. Results: Both IDH-mutant WHO grade 4 astrocytomas (n = 22, 64.7%) and IDH-wildtype… More > Graphic Abstract

    The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory

  • Open Access

    ARTICLE

    Methyltransferase 3A-mediated promoter methylation represses retinoic acid receptor responder 3 expression in basal-like breast cancer

    YOULIN TUO, XUBAO LIU*

    BIOCELL, Vol.47, No.2, pp. 319-328, 2023, DOI:10.32604/biocell.2023.025250 - 18 November 2022

    Abstract Retinoic acid receptor responder 3 (RARRES3) has been characterized as a tumor suppressor in multiple types of cancer. This study aimed to examine the expression profile of RARRES3 across the PAM50 subtypes of breast cancer. The DNA methylation status of RARRES3 was checked in the basal-like subtype, and the underlying mechanisms of its dysregulation were explored. RNA-sequencing (seq) and methylation data from The Cancer Genome Atlas were used for in-silico analysis. Basal-like representative SUM149 and MDA-MB-468 cell lines were used for in vitro and in vivo studies. Compared to tumor-adjacent normal tissues, only the basal-like tumor tissues had… More >

Displaying 1-10 on page 1 of 2. Per Page